Acquired Partial Lipodystrophy (APL)

Acquired partial lipodystrophy (APL) is a rare body-fat disorder that starts after birth (so it is acquired, not present at birth). People gradually lose the normal layer of fat under the skin in a cephalocaudal pattern—that means the fat loss usually begins in the face and then moves downward to the neck, shoulders, arms, chest, and upper abdomen. The hips, buttocks, and legs are often spared, so the lower body can look normal or even relatively fuller compared with the upper body. The process is symmetrical (the same on both sides). Most patients are girls and the first changes often appear in childhood or adolescence. APL is not simply a cosmetic problem: it can be linked to problems of the immune system—especially over-activation of the “alternative” complement pathway—and a risk of kidney disease due to C3 glomerulopathy in some patients. Metabolic problems like high triglycerides or insulin resistance can occur, but are typically less severe than in generalized lipodystrophy. PMC+1OrphaScienceDirectNational Kidney Foundation

Acquired partial lipodystrophy is a very rare condition where body fat slowly disappears from the face and upper body (head, neck, shoulders, arms, chest, sometimes upper abdomen). Fat of the hips and legs often stays the same or may even look bigger, so the body looks “top-lean and bottom-full.” The fat loss usually starts in childhood or the teen years. It can follow a viral illness. It happens more in females. Many people have low blood level of complement C3 and a special antibody called C3 nephritic factor (C3NeF). This antibody can over-activate the alternative complement pathway of the immune system. That can damage fat cells in the face and upper body and, years later in some people, can damage the kidneys (a condition called C3 glomerulopathy or membranoproliferative glomerulonephritis). OrphaGARD Information CenterOxford AcademicRevista Nefrología

Why it happens (pathophysiology)

• In many patients, the C3NeF antibody keeps a complement enzyme (“C3 convertase”) turned on. This causes continuous complement activation. Fat cells make factor D (adipsin), which fuels this pathway. The result can be local complement attack on adipocytes in the upper body and face, with cell lysis and fat loss. This same complement over-activity can also deposit C3 fragments in the kidneys and cause kidney disease later. PMC+1Revista Nefrología

• Typical clinical pattern: gradual, symmetrical loss of subcutaneous fat starting in the face and moving downward (cephalocaudal) to the upper body, often sparing the legs. Onset often in childhood/teens. PMC+1

• Risks to monitor: diabetes or insulin resistance (less common than in other lipodystrophies), high triglycerides, and kidney disease (about 1 in 5 develop C3-related glomerulonephritis after ~8–10 years). GARD Information Center

---

Other names

Doctors and reference sites use several names for this condition:

• Barraquer–Simons syndrome

• Progressive (cephalothoracic) partial lipodystrophy

• Cephalothoracic lipodystrophy
  All of these terms describe the same clinical picture: acquired, symmetric fat loss that starts in the face and spreads down the upper body. OrphaUniProtCheckRare

---

Types

There is one classic pattern of APL, but doctors often discuss clinical sub-types to describe what they see. These sub-types are practical labels rather than strict genetic categories:

1. Classic cephalothoracic APL – the usual pattern: fat loss starts in the face, then moves to neck, shoulders, arms, chest, and upper abdomen; lower body is spared. PMC

2. Classic APL with lower-body lipohypertrophy – the upper body loses fat while thighs/buttocks look relatively fuller after puberty (mostly in women), creating a striking upper–lower contrast. BioMed Central

3. APL with renal involvement – classic pattern plus signs of C3 glomerulopathy (protein in urine, swelling, or biopsy-proven disease). PMC

4. APL with autoimmune overlap – classic pattern plus other autoimmune features or diagnoses (e.g., thyroid autoimmunity), reflecting broader immune dysregulation. ScienceDirect

5. Atypical/variant distribution APL – fat loss begins in an upper-body site other than the face, or facial involvement is minimal (reported but less common). PMC

---

Causes and contributors

APL is multifactorial. Not every person has every factor below, but these are the most discussed contributors in medical literature:

1. Alternative complement pathway over-activation damages selected fat depots. ScienceDirect

2. C3 nephritic factor (C3NeF) keeps complement active and lowers C3 levels. ScienceDirect

3. Low blood C3 itself is a marker of ongoing complement activity and risk to the kidneys. National Kidney Foundation

4. Autoimmune tendency (other autoantibodies or autoimmune diseases in some patients). ScienceDirect

5. Childhood or teen immune “trigger” after a common viral illness has been reported before onset in some series. UT Southwestern

6. Genetic susceptibility (rare reports of LMNB2 variants or other background risk) may set the stage but APL is still “acquired.” Wikipedia

7. Complement factor autoantibodies other than C3NeF (e.g., to factor H/I/B) can contribute in some cases. ScienceDirect

8. Immune complex deposition in small vessels and fat can add local injury. ScienceDirect

9. Panniculitis-like inflammation (inflammation of fat) may precede or accompany local fat loss in some patients. BioMed Central

10. Female sex and puberty-related hormonal context (the disorder is more common in females and appears around puberty). PMC

11. Childhood age of onset (often school age), suggesting immune maturation as a factor. PMC

12. Kidney–complement cross-talk (C3 glomerulopathy) reflects the same immune driver that also affects fat. PMC

13. Ocular complement deposition (drusen-like deposits) reported alongside C3 disease in some cases. PMC

14. Metabolic stress (e.g., high triglycerides) does not cause APL, but once fat is lost, metabolic strain can worsen. Frontiers

15. Pro-inflammatory cytokines from chronic immune activation can harm adipocytes regionally (inference consistent with immune literature). ScienceDirect

16. Environmental infections acting as “first hits” (historical case series note this pattern). UT Southwestern

17. Body-site susceptibility (face/upper body fat depots are more vulnerable to complement-mediated injury). PMC

18. Coexisting autoimmune thyroid disease or other organ-specific autoimmunity (reported associations). ScienceDirect

19. Myopathy association in some patients, suggesting broader immune effects on muscle as well as fat. PMC

20. Unknown factors – many people have no clear trigger; APL remains rare and incompletely understood. PMC

---

Common symptoms and signs

1. Gradual, symmetric fat loss from the face (cheeks look hollow, temples look sunken). PMC

2. Fat loss from the neck, shoulders, and arms over months or years. PMC

3. Flatter upper chest and upper abdomen as subcutaneous fat thins. PMC

4. Lower body looks relatively fuller (buttocks and legs spared; sometimes appear bigger by comparison). BioMed Central

5. Prominent facial bones (cheekbones and chin look sharper). Lippincott Journals

6. Skin may look tight over the face and arms because the fat cushion is missing. PMC

7. Cold intolerance in thin areas because subcutaneous fat helps keep us warm (logical effect of fat loss). PMC

8. Fatigue or reduced exercise tolerance, sometimes linked to muscle involvement or metabolic strain. PMC

9. Self-image distress due to visible body-shape change (a common psychosocial impact in lipodystrophy). Frontiers

10. High triglycerides or low HDL in some patients. Frontiers

11. Mild insulin resistance; diabetes is less common than in generalized lipodystrophy but can occur. PubMed

12. Protein in the urine (proteinuria) or swelling (edema) if the kidneys become involved. National Kidney Foundation

13. Foamy urine from protein loss, a simple home sign of kidney involvement. National Kidney Foundation

14. Possible visual symptoms (rare) from retinal drusen associated with complement disease. PMC

15. History of a viral illness before the first body-shape change in some cases. UT Southwestern

---

Diagnostic tests

A) Physical examination (what the clinician sees and measures)

1. Full body-map inspection – the doctor looks for symmetrical fat loss that starts in the face and extends down the upper body, with lower body sparing. This pattern strongly suggests APL. PMC

2. Serial photographs/measurements – comparing older and recent photos helps confirm progression over time. (Standard clinical practice in lipodystrophy clinics.) Frontiers

3. Blood pressure and edema check – screens for kidney involvement; edema can signal protein loss in urine. National Kidney Foundation

4. Skin and hair look in thin areas – loss of the fat cushion makes veins and bony points more visible; skin may look tight. PMC

5. Signs of insulin resistance – look for acanthosis nigricans, central weight gain elsewhere, or family history; less common but relevant. PubMed

B) Manual / bedside body-composition checks

6. Caliper skin-folds at standard sites (cheek, triceps, subscapular, supra-iliac) to quantify local fat loss over time. (Common bedside method in clinics.) Frontiers

7. Pinch test – gentle pinching of the skin and fat layer to compare upper vs lower body thickness. Frontiers

8. Circumference measurements (mid-arm, waist, hip, thigh) to track proportional changes and calculate waist-to-hip ratio. Frontiers

9. Bioimpedance analysis (simple clinic device) to estimate body-fat percentage and its regional distribution trend. Frontiers

10. Hand-grip strength to screen for muscle involvement or deconditioning if the patient reports weakness or fatigue. PMC

C) Laboratory and pathological tests

11. Fasting lipid panel (triglycerides, HDL, LDL) to look for dyslipidemia linked to lipodystrophy. Frontiers

12. Glucose tests (fasting glucose, HbA1c, sometimes insulin) to check for insulin resistance or diabetes. Frontiers

13. Liver enzymes (ALT, AST, GGT) and sometimes liver fat assessment because abnormal fat handling can affect the liver. Frontiers

14. Serum leptin and adiponectin – often low for the amount of body fat present; this supports a lipodystrophy diagnosis. PMC

15. Complement studies – C3 (often low), sometimes C4; these point toward alternative pathway activation in APL. ScienceDirect

16. C3 nephritic factor (C3NeF) antibody – helps confirm the immune mechanism behind APL when positive. ScienceDirect

17. Autoantibody screen (e.g., ANA, thyroid antibodies) because autoimmunity often coexists. ScienceDirect

18. Urinalysis and urine protein/creatinine ratio – early, noninvasive screen for kidney involvement. National Kidney Foundation

19. Kidney biopsy (only when indicated) – can show C3 glomerulopathy/dense deposit disease if renal disease is suspected. NCBI

20. Skin or fat biopsy (selected cases) – rules out other causes of fat loss (e.g., inflammatory panniculitis) and documents adipose atrophy. BioMed Central

D) Electrodiagnostic tests

21. Electromyography (EMG) – used if there is muscle weakness or myopathy, which can accompany APL in some patients. PMC

22. Nerve conduction studies (NCS) – considered when symptoms suggest neuropathy, for example from coexisting diabetes. Frontiers

23. Electrocardiogram (ECG) – general metabolic risk screening; baseline cardiac assessment is reasonable in systemic lipodystrophy. (General clinical practice reference.) Frontiers

E) Imaging tests

24. Whole-body MRI or regional MRI/CT – clearly shows loss of subcutaneous fat in the upper body with preserved gluteal/lower-limb fat, the classic APL pattern. PMC

25. Dual-energy X-ray absorptiometry (DXA/DEXA) – measures total and regional body fat and tracks changes over time. Frontiers

26. Abdominal ultrasound – checks for fatty liver or other abdominal organ issues linked to dyslipidemia. Frontiers

27. Renal ultrasound – evaluates kidney size and structure in patients with proteinuria or suspected C3G. National Kidney Foundation

28. Ophthalmic imaging (fundus photos/OCT) – looks for drusen-like deposits when complement-mediated eye changes are suspected. PMC

Non-pharmacological treatments

A. Physiotherapy, exercise & lifestyle

1. Structured aerobic training (walking, cycling, swimming)
   Purpose: improve insulin sensitivity and lipid profile.
   Mechanism: increases muscle glucose uptake and uses triglycerides for energy.
   Benefits: lower triglycerides, better blood sugar, better stamina and mood. PMC

2. Progressive resistance training (2–3 days/week)
   Purpose: build lean mass to support metabolism and posture.
   Mechanism: stimulates muscle protein synthesis and GLUT-4 translocation.
   Benefits: better insulin sensitivity, stronger shoulders/back to balance contour.

3. Interval training (as tolerated)
   Purpose: faster improvement in cardio-metabolic health.
   Mechanism: brief high-effort bouts elevate mitochondrial function.
   Benefits: lowers triglycerides and improves fitness with short sessions.

4. Core and postural therapy
   Purpose: counter upper-body muscular imbalance as fat volume falls.
   Mechanism: strengthens scapular stabilizers and trunk muscles.
   Benefits: better shoulder/neck comfort, improved body image in clothing.

5. Flexibility and mobility work
   Purpose: reduce stiffness from altered mechanics.
   Mechanism: lengthens tight muscle groups; improves joint range.
   Benefits: easier exercise, less pain, better daily function.

6. Low-fat, balanced diet with portion control
   Purpose: reduce hypertriglyceridemia risk.
   Mechanism: lower intake of saturated fat and simple sugars reduces VLDL output.
   Benefits: supports safer triglyceride levels; pairs well with medicines when needed. PMC

7. High-fiber pattern (vegetables, pulses, whole grains)
   Purpose: smooth post-meal glucose and lipids.
   Mechanism: viscous fiber slows absorption; feeds gut microbiome.
   Benefits: better satiety, possible triglyceride reduction.

8. Omega-3–rich foods (fish 2–3×/week, walnuts, flax)
   Purpose: support triglyceride control and anti-inflammatory tone.
   Mechanism: EPA/DHA reduce hepatic VLDL synthesis and may resolve lipid stress.
   Benefits: adjunct to meds; heart-friendly.

9. Limit alcohol
   Purpose: alcohol spikes triglycerides and stresses liver.
   Mechanism: increases hepatic lipogenesis and impairs fat oxidation.
   Benefits: fewer pancreatitis/liver risks in high-TG patients.

10. Sleep hygiene (7–9 hours)
    Purpose: support insulin sensitivity and appetite control.
    Mechanism: normalizes leptin/ghrelin rhythms; reduces cortisol.
    Benefits: easier weight and glucose management.

11. Smoking cessation
    Purpose: protect kidneys and heart.
    Mechanism: reduces endothelial injury and oxidative stress.
    Benefits: lower cardiovascular and renal progression risk.

12. Sun and skin care for facial contour
    Purpose: protect delicate facial skin after reconstructive procedures/fillers.
    Mechanism: SPF and gentle care preserve collagen and procedure results.
    Benefits: better cosmetic outcomes (evidence stronger in aesthetic literature). PubMed

13. Compression/garment tailoring
    Purpose: balance silhouette when lower-body fat is prominent.
    Mechanism: graded compression and clothing strategies redistribute visual lines.
    Benefits: body-image support; non-medical but meaningful.

14. Registered dietitian follow-up
    Purpose: create sustainable, enjoyable eating plan for labs and energy.
    Mechanism: personalized macronutrients; supports adherence to medical therapy.
    Benefits: better triglycerides, glucose, and liver enzymes over time. PMC

15. Regular kidney-health monitoring
    Purpose: catch C3 glomerulopathy early.
    Mechanism: routine urine protein tests, creatinine/eGFR, blood pressure checks.
    Benefits: early ACEi/ARB and specialist care if proteinuria appears. Wikipedia

B. Mind-body therapies

16. Cognitive-behavioral therapy (CBT) for body image
    Purpose: reduce distress and social withdrawal due to facial changes.
    Mechanism: reframing thoughts, exposure practice, coping skills.
    Benefits: higher quality of life; better adherence to medical care. PMC

17. Mindfulness/relaxation training
    Purpose: manage stress that can worsen metabolic control.
    Mechanism: lowers sympathetic tone and cortisol.
    Benefits: small improvements in glucose and well-being.

18. Peer support groups / rare-disease communities
    Purpose: reduce isolation; share practical tips and surgeon/clinic experience.
    Mechanism: social support improves coping and follow-through.
    Benefits: better mental health and informed decisions. PMC

19. Graded activity pacing
    Purpose: rebuild confidence after fatigue or deconditioning.
    Mechanism: small, regular increases in activity prevent over-exertion.
    Benefits: sustainable habit formation.

20. Sleep-focused CBT (CBT-I) when insomnia is present
    Purpose: improve sleep to support metabolic health.
    Mechanism: stimulus control and sleep scheduling.
    Benefits: steadier appetite and energy.

C. Educational therapy

21. Disease education about complement and kidney risk
    Purpose: explain why urine and blood tests matter.
    Mechanism: knowledge improves adherence to monitoring.
    Benefits: earlier detection and treatment of C3G if it arises. Cleveland Clinic Journal of Medicine

22. Medication literacy
    Purpose: how and when to take meds (e.g., metformin with meals, statin at night depending on agent).
    Mechanism: prevents side effects and improves effectiveness.
    Benefits: safer, steadier control. PMC

23. Food label and meal-planning skills
    Purpose: identify hidden sugars and fats.
    Mechanism: simple label rules and plate method.
    Benefits: lower TG and glucose variability.

24. Procedure counseling (fillers, fat transfer, implants)
    Purpose: set realistic expectations and maintenance plans.
    Mechanism: discuss resorption rates, repeat sessions, and risks.
    Benefits: higher satisfaction and safer choices. SpringerLinkPMC

25. Family education about supportive communication
    Purpose: reduce stigma and improve daily support.
    Mechanism: teach helpful language and boundaries.
    Benefits: better mental health and adherence.

---

Drug treatments

Important: There is no pill that “re-grows” the lost fat in APL. Medicines target complications (lipids, glucose, blood pressure, kidney risk) and, in selected cases, complement dysregulation. Always use under specialist care.

1. Metreleptin (recombinant leptin; daily SC injection)
   Class: hormone replacement.
   Dose/time: individualized; daily subcutaneous; specialist centers; REMS in US.
   Purpose: treat metabolic complications in leptin-deficient lipodystrophy; sometimes used in partial forms with severe hypertriglyceridemia or diabetes and low leptin.
   Mechanism: restores leptin signaling → improves insulin resistance, TG, liver fat.
   Side effects: injection site reactions; headaches; rare lymphoma signal and anti-drug antibodies; requires monitoring. PMC

2. Metformin
   Class: insulin sensitizer (biguanide).
   Dose/time: 500–2000 mg/day with meals.
   Purpose: insulin resistance or diabetes.
   Mechanism: reduces hepatic glucose output; improves peripheral uptake.
   Side effects: GI upset; rare lactic acidosis in CKD. PMC

3. Insulin (basal/bolus or premix)
   Class: hormone therapy.
   Purpose: when hyperglycemia is not controlled with or without metformin; in severe hypertriglyceridemia crises.
   Mechanism: promotes glucose uptake and lipogenesis suppression.
   Side effects: hypoglycemia, weight change. PMC

4. GLP-1 receptor agonists (e.g., liraglutide, semaglutide)
   Purpose: improve glycemia and weight distribution where appropriate.
   Mechanism: enhances glucose-dependent insulin secretion; slows gastric emptying.
   Side effects: nausea; gallbladder issues; avoid in specific thyroid cancers. PMC

5. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)
   Purpose: glucose lowering with heart/kidney benefits.
   Mechanism: increases urinary glucose excretion; cardiorenal protection.
   Side effects: genital infections; rare ketoacidosis risk. PMC

6. Statins
   Purpose: LDL control and CV risk reduction.
   Mechanism: HMG-CoA reductase inhibition.
   Side effects: myalgias, liver enzyme rise. PMC

7. Fibrates (fenofibrate)
   Purpose: high triglycerides.
   Mechanism: PPAR-α agonism lowers VLDL/TG.
   Side effects: myopathy risk (esp. with statins), ↑creatinine—caution in CKD. PMC

8. Omega-3 ethyl esters / Icosapent ethyl
   Purpose: lower TG; pancreatitis risk reduction.
   Mechanism: reduce hepatic VLDL synthesis; anti-inflammatory lipid mediators.
   Side effects: GI upset; bleeding risk with anticoagulants. PMC

9. ACE inhibitors (e.g., ramipril) or ARBs (e.g., losartan)
   Purpose: treat proteinuria and protect kidneys when C3G risk or hypertension exists.
   Mechanism: reduces intraglomerular pressure; antiproteinuric.
   Side effects: cough (ACEi), hyperkalemia, ↑creatinine. PMC

10. Eculizumab (anti-C5 monoclonal antibody)
    Purpose: selected cases of rapidly progressive C3 glomerulopathy; off-label.
    Mechanism: blocks terminal complement C5, reducing membrane attack complex.
    Side effects: meningococcal infection risk (vaccination needed); high cost. Evidence shows mixed renal responses; may help aggressive disease. BioMed CentralPMCFrontiers

11. Iptacopan (Fabhalta) – oral factor B inhibitor
    Purpose: C3 glomerulopathy; as of March 20, 2025, FDA-approved for adults with C3G (first approval for this disease).
    Mechanism: blocks alternative pathway at factor B.
    Benefits/side effects: trials show clinically meaningful proteinuria reduction and eGFR stabilization; monitor for infection and lab changes. Drugs.comNovartisCleveland Clinic Journal of Medicine

12. Pegcetacoplan (C3 inhibitor)
    Purpose: investigational/expanding use for C3G and primary IC-MPGN; strong Phase 3 VALIANT data with large proteinuria reductions; regulatory status evolving by region.
    Mechanism: inhibits C3/C3b to calm complement activation.
    Side effects: injection-site reactions; infection risk; monitoring needed. Lippincott JournalsApellis InvestorsHCP Live

13. Mycophenolate mofetil + low-dose steroids (for C3G)
    Purpose: some cohorts show remission rates better than calcineurin inhibitors in immune-mediated patterns.
    Mechanism: lymphocyte proliferation blockade; reduces inflammation.
    Side effects: GI upset, infection risk, cytopenias. Frontiers

14. Pioglitazone (selected cases with insulin resistance)
    Purpose: insulin sensitization; may modestly affect subcutaneous fat distribution in some lipodystrophy contexts; use judiciously.
    Mechanism: PPAR-γ agonist.
    Side effects: edema, weight gain, fracture risk. (Use is individualized; evidence in APL is limited.) NCBI

15. Omega-3-only medical foods / high-dose formulations
    Purpose: adjunct for severe TG when fibrates/statins are not enough.
    Mechanism/Side effects: as in #8; used under clinician oversight. PMC

Note: Medication choices depend on your actual lab values, leptin level, kidney status, blood pressure, age, and comorbidities. A lipodystrophy-experienced endocrinologist or nephrologist should guide therapy. PMC

---

Dietary molecular supplements

1. Prescription-strength omega-3 (EPA/DHA or EPA-only) — typical 2–4 g/day in divided doses; function: lowers triglycerides by reducing hepatic VLDL; mechanism: substrate and gene-level effects on lipid handling. PMC

2. Soluble fiber (psyllium, beta-glucan; ~10–15 g/day) — function: smooths glucose and TG peaks; mechanism: slows absorption and improves bile acid metabolism.

3. Vitamin D (dose per level, often 1000–2000 IU/day) — function: bone and immune support; mechanism: nuclear receptor effects; avoid overdose.

4. Magnesium (200–400 mg/day) — function: supports insulin signaling and muscle function; mechanism: cofactor in glucose transport; watch kidneys.

5. Alpha-lipoic acid (300–600 mg/day) — function: antioxidant; may aid neuropathic symptoms and insulin action; mechanism: redox cycling in mitochondria.

6. Coenzyme Q10 (100–200 mg/day) — function: mitochondrial support; mechanism: electron transport; may ease statin myalgias.

7. Plant sterols/stanols (~2 g/day) — function: small LDL reduction; mechanism: compete with cholesterol absorption.

8. Taurine (1–2 g/day) — function: potential TG and bile acid effects; mechanism: conjugation and membrane stabilization; evidence modest.

9. Niacin (only with specialist oversight) — function: lowers TG/raises HDL but can worsen glucose; mechanism: reduces hepatic lipolysis.

10. Curcumin with piperine (standardized) — function: anti-inflammatory adjunct; mechanism: NF-κB modulation; variable bioavailability.

(Evidence quality for items 5–10 ranges from modest to limited; they should not replace prescription therapy.)

---

Regenerative / stem-cell drugs

Important safety note: There are no approved stem-cell or “immunity booster” drugs that restore lost fat in APL. Using stem cells or “boosters” outside clinical trials is not evidence-based and may be unsafe. What is evidence-based for the immune/complement problem are complement inhibitors for C3 glomerulopathy (e.g., eculizumab, iptacopan, pegcetacoplan) under specialist care. Below are 6 immune-modulating options with real evidence for complications related to APL; these are not stem-cell drugs:

1. Iptacopan (oral Factor B inhibitor) — see above #11; dose/time: per label for C3G; function: reduce proteinuria, stabilize eGFR by blocking alternative pathway; mechanism: Factor B blockade; note: FDA-approved for C3G in 2025. Drugs.com

2. Pegcetacoplan (C3/C3b inhibitor, SC) — dose/time: per protocol; function: large proteinuria reductions in Phase 3 VALIANT; mechanism: proximal C3 inhibition; status: regulatory pathways ongoing/region-dependent. Lippincott JournalsApellis Investors

3. Eculizumab (C5 inhibitor, IV) — function: may help rapidly progressive C3G; mechanism: blocks membrane attack complex; note: mixed outcomes; vaccine required. BioMed Central

4. Mycophenolate mofetil + low-dose steroids — function: immunosuppression in C3G/immune-complex patterns; mechanism: lymphocyte proliferation blockade; evidence: cohorts suggest higher response than some alternatives. Frontiers

5. ACEi/ARB (renal protective) — function: reduce proteinuria and slow renal decline; mechanism: RAAS modulation; status: standard of care in proteinuric kidney disease. PMC

6. SGLT2 inhibitors (kidney-heart protection) — function: reduce CKD progression and CV events in diabetes; mechanism: tubuloglomerular feedback and metabolic effects; use: adjunct when diabetes coexists. PMC

(If you were hoping for “stem-cell” medicines to regrow fat, current science does not support that for APL. Please consider clinical trials only.)

---

Surgeries / procedures

1. Autologous fat transfer (lipofilling / microfat / nanofat)
   Procedure: harvest your fat (often thighs/abdomen), process, inject into face/deficit areas.
   Why done: restore lost contours with your own tissue.
   Notes: some resorption over time; sessions may be repeated; outcomes can be good but may require maintenance. SpringerLinkSynapse

2. Dermal fillers (e.g., hyaluronic acid; poly-L-lactic acid/PLLA)
   Procedure: office injections to add volume or stimulate collagen.
   Why done: less invasive, adjustable.
   Notes: PLLA can need multiple sessions and may cause papules; HA is reversible. Widely used for facial lipoatrophy (strongest evidence in HIV-related lipoatrophy). PubMed

3. Facial implants (malar/cheek, chin) in selected cases
   Procedure: silicone or other implants to rebuild structure.
   Why done: durable contour when soft-tissue options fail.
   Notes: higher invasiveness; discuss risks and revision plans (evidence mostly from aesthetic surgery literature).

4. Free-flap soft-tissue transfers (e.g., TRAM flaps)
   Procedure: move vascularized tissue from another body site to face/deficit.
   Why done: for severe cases needing bulk and durability.
   Notes: major surgery; longer downtime; case reports show feasibility. PMC

5. Body-contouring liposuction (lower body)
   Procedure: targeted liposuction of hips/thighs if disproportion bothers function or clothing fit.
   Why done: improve silhouette balance when lower body is relatively prominent.
   Notes: does not treat disease; cosmetic balance only. PMC

(Choice depends on your goals, donor fat availability, cost, and surgeon expertise. Expect touch-ups for fat grafting and PLLA.)

---

Preventions

1. Regular kidney checks (urine protein, creatinine/eGFR, blood pressure). Early nephrology referral if proteinuria. Cleveland Clinic Journal of Medicine

2. Control triglycerides (diet + meds) to prevent pancreatitis. PMC

3. Vaccinations up to date; meningococcal vaccine is required before complement inhibitors. BioMed Central

4. Avoid smoking to protect vessels and kidneys.

5. Limit alcohol to protect liver and triglycerides.

6. Consistent exercise (aerobic + resistance) to maintain insulin sensitivity. PMC

7. Medication adherence and follow-up with specialists experienced in lipodystrophy. PMC

8. Manage blood pressure (target as advised) to protect kidneys.

9. Safe choice of cosmetic providers (qualified dermatology/plastic surgery experienced with lipoatrophy). SpringerLink

10. Early mental-health support to prevent anxiety/depression spirals that harm self-care. PMC

---

When to see doctors

• Right away / urgent:
  • New swelling of legs/face, foamy urine, blood in urine, or sudden rise in BP → could be kidney involvement. Cleveland Clinic Journal of Medicine
  • Severe abdominal pain with very high triglycerides (risk of pancreatitis).
  • Fever/neck stiffness if on complement inhibitors (meningococcal risk). BioMed Central

• Soon (planned visit):
  • You notice new or spreading fat loss.
  • Lab changes: rising TG, low C3, protein in urine. GARD Information Center
  • You want to discuss metreleptin, GLP-1/SGLT2, or complement-targeted therapy due to kidney findings. PMCDrugs.com
  • You are considering fillers/fat transfer and want a surgical plan. SpringerLink

---

What to eat” and “what to avoid

Eat more of:

1. Vegetables and salads (aim half your plate).

2. Lean proteins (fish, skinless poultry, tofu, pulses).

3. Whole grains (brown rice, oats) in modest portions.

4. High-fiber foods (beans, lentils, barley, psyllium).

5. Omega-3 fish (salmon, sardine, hilsa) 2–3×/week. PMC

Limit/Avoid:

1. Sugary drinks and sweets (spike TG and glucose).
2. Refined starches (white bread, noodles in large amounts).
3. Saturated/trans fats (deep-fried, bakery shortenings).
4. Heavy alcohol (raises TG; liver stress).
5. Excess salt if you have high BP or proteinuria (kidney-protective). PMC

---

Frequently asked questions

1. Is APL genetic?
   No. APL is acquired. Some reports show links to immune factors like C3NeF; very rarely, research has explored LMNB2, but routine genetic causes are not established here. Orpha

2. Why does fat vanish from the face first?
   Because adipocytes in the face/upper body may express more adipsin (factor D). With C3NeF, complement may attack these cells more. PMC

3. Can the lost fat grow back by itself?
   Usually no. Appearance is improved with fillers or fat transfer. PubMed

4. Will I get diabetes?
   Some people in APL have insulin resistance, but rates are lower than in generalized lipodystrophy. You still need healthy living and regular labs. PMC

5. How common is kidney disease in APL?
   About 1 in 5 develop C3-related glomerulonephritis, often years after fat loss. So regular urine and blood checks are vital. GARD Information Center

6. Is metreleptin for everyone with APL?
   No. It helps leptin-deficient patients with severe metabolic problems; it is approved mainly for generalized forms, but partial forms with severe disease and low leptin may benefit in expert centers. PMC

7. Are there oral drugs for complement problems?
   Yes. Iptacopan (factor B inhibitor) is now FDA-approved for C3G (2025). It targets the root alternative pathway. Drugs.com

8. What about pegcetacoplan?
   It targets C3 and showed large proteinuria reductions in the VALIANT Phase 3 trial; availability depends on region/regulatory updates. Lippincott Journals

9. Is eculizumab still used?
   Sometimes, for rapidly progressive C3G. Responses are variable; meningococcal vaccination is required. BioMed Central

10. Can diet alone fix APL?
    Diet helps triglycerides and glucose, not the fat loss pattern. Combine diet with medical care and, if desired, cosmetic procedures. PMC

11. Are stem-cell shots a cure?
    No. There is no proven stem-cell cure for APL. Avoid unregulated treatments. Consider clinical trials only.

12. Is surgery permanent?
    Implants are durable; fat grafting and PLLA may need repeat sessions. Outcomes depend on surgeon skill and aftercare. SpringerLink

13. What tests should I get now?
    Fasting glucose, lipid panel, creatinine/eGFR, urine protein, C3 level, and if advised C3NeF and other autoantibodies; imaging if diagnosis is unclear. Wikipedia

14. Can children have APL?
    Yes. Onset often in childhood. Pediatric endocrinology and nephrology should follow them long term. UT Southwestern

15. What specialists do I need?
    Endocrinology (lipodystrophy experience), nephrology (for C3G risk), and dermatology/plastic surgery for reconstruction; plus dietitian and mental-health support. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 02, 2025.